Zimmer Biomet (ZBH)

The company is best known for large-joint reconstruction, particularly knee and hip implants. These products are used in procedures such as total knee replacement, partial knee replacement, and hip arthroplasty, markets supported by aging populations, osteoarthritis prevalence, and patient demand for mobility and pain relief. Large joints account for the majority of Zimmer Biomet’s revenue, making procedure volumes, hospital purchasing behavior, surgeon preference, and innovation in implant design important drivers of performance.

Beyond hips and knees, Zimmer Biomet sells products in areas including extremities, trauma, sports medicine, surgical tools, and biologics-related offerings. The company also invests in digital and robotic-assisted surgery platforms intended to improve surgical planning, precision, and workflow. In orthopedics, these technologies can help deepen relationships with hospitals and surgeons, although adoption depends on clinical outcomes, training, capital budgets, and competitive alternatives.

Zimmer’s market position was shaped by major acquisitions, including Centerpulse in 2003 and Biomet in 2015, which expanded its product portfolio and global reach. The company later separated its dental and spine businesses, sharpening its focus on orthopedics and musculoskeletal care. Zimmer Biomet competes with other large medtech firms in a highly regulated industry where product quality, clinical evidence, surgeon loyalty, manufacturing reliability, and reimbursement conditions all matter. Its business is closely tied to elective procedure trends, hospital capacity, and long-term demand for joint replacement worldwide.